Differential screening-selected gene aberrative in neuroblastoma (DAN) is increased in the CSF of patients with MS and may be induced by therapy with interferon-β

• Published in: Journal of neuroimmunology 2016-03, Vol.292, p.93-96
• Main Authors: Mausner-Fainberg, Karin, Kolb, Hadar, Penn, Moran, Regev, Keren, Vaknin-Dembinsky, Adi, Gadoth, Avi, Kestenbaum, Meir, Karni, Arnon
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Allergy and Immunology; Antibodies - cerebrospinal fluid; Bone Morphogenetic Proteins - antagonists & inhibitors; Bone Morphogenetic Proteins - immunology; Bone morphogenic proteins; Cells, Cultured; Cerebrospinal fluid; Differential screening-selected gene aberrative in neuroblastoma (DAN); Female; Gene Expression Regulation - drug effects; Humans; Interferon-beta - therapeutic use; Interferon-β; Male; Middle Aged; Monocytes - drug effects; Multiple sclerosis; Multiple Sclerosis - cerebrospinal fluid; Multiple Sclerosis - drug therapy; Neuroblastoma - cerebrospinal fluid; Neuroblastoma - genetics; Neurogenesis; Neurology; Oligodendrogenesis; Proteins - metabolism; Young Adult
• ISSN: 0165-5728; 1872-8421
• DOI: 10.1016/j.jneuroim.2016.01.019

Abstract Bone morphogenic proteins (BMPs) signaling blockade induce neurogenesis and oligodendrogenesis. Differential screening-selected gene aberrative in neuroblastoma (DAN) is a glycoprotein that antagonizes BMPs. We found that DAN levels were higher in CSF compared to serum in all participants. CSF-DAN levels were elevated in RR-and progresssive MS patients compared to controls. Moreover, serum-DAN levels were reduced in those patients, but elevated in IFN-β1a treated patients. The main source of DAN is apparently CNS- resident cells. The enhanced levels of CSF-DAN in MS patients suggest a tendency to induce neurogenesis/oligodendrogenesis in the patients CNS. Our results suggest an unreported mode of action of IFN-β1a.